An inhaled "bifunctional" dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD

Eur Respir J. 2018 Nov 1;52(5):1801675. doi: 10.1183/13993003.01675-2018. Print 2018 Nov.

Authors

Mario Cazzola¹, Clive Page²

Affiliations

¹ Unit of Respiratory Medicine, Dept of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy.
² Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, UK.

PMID: 30385603
DOI: 10.1183/13993003.01675-2018

No abstract available

Publication types

Editorial
Comment

MeSH terms

Bronchodilator Agents*
Humans
Isoquinolines
Phosphoric Diester Hydrolases
Pulmonary Disease, Chronic Obstructive*
Pyrimidinones

Substances

Bronchodilator Agents
Isoquinolines
Pyrimidinones
ensifentrine
Phosphoric Diester Hydrolases